Short Interest in Biorestorative Therapies, Inc. (NASDAQ:BRTX) Declines By 32.4%

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totaling 890,908 shares, a decline of 32.4% from the March 15th total of 1,318,064 shares. Currently, 5.1% of the shares of the company are short sold. Based on an average daily trading volume, of 3,378,307 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On Biorestorative Therapies

A number of hedge funds have recently modified their holdings of BRTX. Virtu Financial LLC boosted its position in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares during the period. Citadel Advisors LLC bought a new position in shares of Biorestorative Therapies in the third quarter worth approximately $152,000. Finally, DRW Securities LLC bought a new position in shares of Biorestorative Therapies in the fourth quarter worth approximately $55,000. 69.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biorestorative Therapies has an average rating of “Sell”.

Biorestorative Therapies Trading Up 6.8%

Shares of NASDAQ BRTX opened at $0.26 on Tuesday. The firm has a 50 day moving average of $0.35 and a 200 day moving average of $0.96. The firm has a market capitalization of $6.55 million, a price-to-earnings ratio of -0.16 and a beta of 0.37. Biorestorative Therapies has a 12-month low of $0.19 and a 12-month high of $2.05.

Biorestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.15 million. Biorestorative Therapies had a negative net margin of 3,956.11% and a negative return on equity of 430.91%. Sell-side analysts predict that Biorestorative Therapies will post -1.43 EPS for the current year.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.